Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

781
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
781
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

5.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-formulation of IL-12 mRNA and doxorubicin in polymeric nanoparticles for simultaneous delivery in murine melanoma.

RSC pharmaceutics·2026
Same author

Composite biomaterials of polyelectrolyte complex micelle nanoparticles in hyaluronic acid gels enable local, targeted miR-92a inhibition and enhanced angiogenesis in diabetic wound repair.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Corrigendum to 'Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant' [Biomaterials, 128 (2021), 121159].

Biomaterials·2026
Same author

Serum albumin-fused interleukin-10 prevents neuroinflammation by promoting immunoregulation in the secondary lymphoid organs and limiting immune cell infiltration in the spinal cord.

bioRxiv : the preprint server for biology·2026
Same author

Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and Atherosclerosis.

bioRxiv : the preprint server for biology·2026
Same author

LDL-binding IL-10 reduces vascular inflammation in atherosclerotic mice.

Nature biomedical engineering·2026

Related Experiment Video

Updated: Oct 29, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.0K

Immunoengineering approaches for cytokine therapy.

Aslan Mansurov1, Abigail Lauterbach1, Erica Budina1

  • 1Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois.

American Journal of Physiology. Cell Physiology
|July 7, 2021
PubMed
Summary

Protein engineering improves therapeutic cytokines for cancer and autoimmune diseases. Modified cytokines offer better safety and efficacy than wild-type versions, overcoming previous limitations.

Keywords:
cytokinedrug delivery systemimmuno-engineeringimmunotherapyinflammation

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.1K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

585

Related Experiment Videos

Last Updated: Oct 29, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.0K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.1K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

585

Area of Science:

  • Biotechnology
  • Immunology
  • Drug Development

Background:

  • Cytokines are crucial signaling molecules with therapeutic potential for cancer and autoimmune diseases.
  • Current cytokine therapies face challenges with toxicity, limited efficacy, and unfavorable pharmacokinetics.
  • Wild-type cytokines often cause systemic side effects or do not remain in target organs long enough.

Purpose of the Study:

  • To review protein-engineering strategies for enhancing cytokine therapeutic indices.
  • To highlight the relevance of engineered cytokines in treating specific diseases.
  • To address limitations of wild-type cytokines in clinical applications.

Main Methods:

  • Review of protein-engineering techniques applied to cytokines.
  • Analysis of pharmacokinetic and pharmacodynamic improvements.
  • Examination of clinical relevance in various disease contexts.

Main Results:

  • Protein engineering can significantly enhance cytokine therapeutic efficacy and safety.
  • Modified cytokines demonstrate improved residence time in secondary lymphoid organs.
  • Engineered cytokines offer a promising alternative to wild-type versions.

Conclusions:

  • Protein engineering is a viable strategy to overcome the limitations of cytokine therapeutics.
  • Engineered cytokines hold significant promise for treating cancer and autoimmune disorders.
  • Further development of engineered cytokines could expand their clinical application.